Opko Health Inc. (NASDAQ:OPK) Director Richard C. Pfenniger, Jr. Purchases 30,000 Shares

Opko Health Inc. (NASDAQ:OPK) Director Richard C. Pfenniger, Jr. acquired 30,000 shares of the stock in a transaction dated Wednesday, May 22nd. The stock was purchased at an average cost of $2.05 per share, with a total value of $61,500.00. Following the purchase, the director now directly owns 250,000 shares of the company’s stock, valued at $512,500. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Shares of OPK traded down $0.05 during trading hours on Friday, reaching $1.90. 2,485,331 shares of the company’s stock traded hands, compared to its average volume of 4,932,518. The company has a market cap of $1.18 billion, a PE ratio of -7.60 and a beta of 1.92. The company has a current ratio of 1.10, a quick ratio of 0.99 and a debt-to-equity ratio of 0.13. Opko Health Inc. has a 12 month low of $1.73 and a 12 month high of $6.40.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.08). The firm had revenue of $222.50 million for the quarter, compared to analysts’ expectations of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The business’s quarterly revenue was down 12.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.08) earnings per share. As a group, analysts predict that Opko Health Inc. will post -0.42 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of OPK. Teachers Advisors LLC increased its stake in shares of Opko Health by 3.5% during the third quarter. Teachers Advisors LLC now owns 754,427 shares of the biotechnology company’s stock valued at $2,610,000 after buying an additional 25,222 shares during the period. Vanguard Group Inc. boosted its position in shares of Opko Health by 2.1% during the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Strs Ohio boosted its position in shares of Opko Health by 27.0% during the fourth quarter. Strs Ohio now owns 112,500 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 23,900 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Opko Health by 36.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 23,049 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 6,097 shares in the last quarter. Finally, Fosun International Ltd boosted its position in shares of Opko Health by 38.9% during the fourth quarter. Fosun International Ltd now owns 768,142 shares of the biotechnology company’s stock valued at $1,943,000 after purchasing an additional 215,000 shares in the last quarter. 25.35% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently commented on OPK. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a research report on Friday, March 8th. ValuEngine downgraded Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Barrington Research restated a “buy” rating and issued a $5.00 target price on shares of Opko Health in a research note on Thursday, February 28th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $9.25.

ILLEGAL ACTIVITY WARNING: This article was first posted by Sundance Herald and is the sole property of of Sundance Herald. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://sundanceherald.com/2019/06/14/insider-buying-opko-health-inc-opk-director-purchases-30000-shares-of-stock.html.

Opko Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply